SCHEMBL12980

SCHEMBL12980

Cc1cccc(N2CCOCC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.62
LMNA P02545 1/20 0.59
MAPT P10636 8/20 0.58
ALDH1A1 P00352 6/20 0.58
MAPK1 P28482 2/20 0.58
PKM P14618 1/20 0.58
KCNH2 Q12809 2/20 0.56
KMO O15229 1/20 0.56
AGXT P21549 1/20 0.53
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KDM4E B2RXH2 4/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TP53 P04637 2/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52
HTT P42858 1/20 0.52
HSD17B10 Q99714 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10373770 0.86 ADRB1 (0.74) ADRB1MAPTALDH1A1KCNH2RAB9A
SCHEMBL27329825 0.86 LMNA (0.71) LMNAMAPTALDH1A1MAPK1PKM
SCHEMBL11103700 0.86 ADRB1 (0.74) ADRB1MAPTALDH1A1KCNH2RAB9A
SCHEMBL3878738 0.85 MAPT (0.55) ADRB1LMNAMAPTALDH1A1MAPK1
SCHEMBL12879720 0.84 ALDH1A1 (0.53) ADRB1MAPTALDH1A1MAPK1PKM
SCHEMBL11096302 0.84 KCNH2 (0.73) ADRB1LMNAMAPTALDH1A1KCNH2
SCHEMBL13525286 0.82 MAPT (0.52) LMNAMAPTALDH1A1MAPK1PKM
SCHEMBL8264176 0.82 ADRB1 (0.69) ADRB1LMNAMAPTALDH1A1KCNH2
SCHEMBL12991 0.82 ADRB1 (0.69) ADRB1MAPTALDH1A1KCNH2AGXT
SCHEMBL17281442 0.80 ADRB1 (0.67) ADRB1LMNAMAPTALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113135835-A Method for exciting C-C bond breaking acylation and application 广州中医药大学(广州中医药研究院) 2021-07-20 CN claimed
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 EP disclosed
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 WO disclosed
EP-4310084-A1 PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF Jinan University (CN) 2024-01-24 EP disclosed
WO-2023237759-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR ANAGENESIS BIOTECHNOLOGIES (FR) 2023-12-14 WO disclosed
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS ENYO PHARMA (FR) 2023-10-12 US disclosed
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS ENYO PHARMA (FR) 2023-10-12 US disclosed
US-11767316-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-09-26 US disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
WO-2023122594-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED (US) 2023-06-29 WO disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
EP-1133475-A1 SUBSTITUTED BENZO DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GmbH (DE) 2001-09-19 EP disclosed
WO-2000031039-A1 SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GMBH (DE) 2000-06-02 WO disclosed
US-4923974-A COLORFASTNESS, BRIGHTNESS, BUILD-UP SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-05-08 US disclosed
US-4898941-A Process for preparing diphenylalkene derivatives KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1990-02-06 US disclosed
EP-0257591-A2 Process for preparing diphenylalkene derivatives KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1988-03-02 EP disclosed
EP-0015872-B1 CATIONIC AZODYESTUFFS, THEIR PREPARATION AND THEIR USE IN DYEING AND PRINTING TEXTILE MATERIAL CIBA-GEIGY AG (CH) 1983-03-30 EP disclosed
US-4288589-A Cationic dyes CIBA-GEIGY CORPORATION (US) 1981-09-08 US disclosed
EP-0015872-A1 Cationic azodyestuffs, their preparation and their use in dyeing and printing textile material CIBA-GEIGY AG (CH) 1980-09-17 EP disclosed
US-4046752-A Process for preparing an azo compound from a 2-aminothiazole diazo component HOECHST AKTIENGESELLSCHAFT (DT) 1977-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767316-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH ADRB1 4718/4885LMNA 4792/4885MAPT 2844/4885
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 ADRB1 34/4885LMNA 4065/4885MAPT 2814/4885
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS TST, TPMT, MMP1 ADRB1 1614/4885LMNA 4369/4885MAPT 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.